Strengthen Village Malaria Reporting to Better Target Reservoirs of Persistent Infections in Southeast Asia

Abstract

References 1. Sekaggya-Wiltshire C, von Braun A, Lamorde M, et al. Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations. Clin Infect Dis 2018; 67:708–16. 2. Heysell SK, Mtabho C, Mpagama S, et al. Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Chemother 2011; 55:5819–25. 3. Pasipanodya JG, Gumbo T. Individualizing tuberculosis (TB) treatment: are TB programs in high burden settings ready for prime time therapeutic drug monitoring? Clin Infect Dis 2018; 67:717–8. 4. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169–83. 5. Alffenaar JC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP. Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis 2017; 64:104–5. 6. World Health Organization. Rapid communication: key changes to treatment of multidrugand rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva, Switzerland: WHO, 2018. 7. Zentner I, Schlecht HP, Khensouvann L, et al. Urine colorimetry to detect low rifampin exposure during tuberculosis therapy: a proof-of-concept study. BMC Infect Dis 2016; 16:242. 8. van den Elsen SHJ, Oostenbrink LM, Heysell SK, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit 2018; 40:17–37. 9. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63:e147–95. 10. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis 2017; 17:125. 11. World Health Organization. Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. 2018. Available at: http://apps.who.int/iris/bitstream/handle/10665/ 260440/WHO-CDS-TB-2018.6-eng.pdf. Accessed 23 August 2018.